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fractionation schedules. When 2 Gy equivalent doses to the rectum or 
bladder (EQD2 assuming rectal/bladder a/b=3) were compared 
between those suffering from Gr 2 toxicity or less, we found absolute 
dose-volumes to be better predictors than relative dose-volumes. 
Those with Gr 2 GI toxicity had a significantly higher V50GyEQD2 (29.7cc 
vs. 17.8cc, p=0.01) and V60GyEQD2 (27.6cc vs. 18.4cc, p=0.04). Higher 
dose volumes were not different. Those with Gr 2 GU toxicity had a 
significantly higher V70GyEQD2 (36.6cc vs. 18.7cc, p=0.004) and 
V65GyEQD2 (36.8cc vs. 19.0cc, p =0.004). ROC curve analysis showed 
that V50GyEQD2> 17.3cc and V60GyEQD2 > 9.8cc were best thresholds for 
Gr 2 GI toxicity.Reliable threshold estimates were not obtained for GU 
toxicity due to small numbers with Gr 2 toxicity. 
Conclusions: Moderate hypofractionation with IG-IMRT is well-
tolerated, even with elective pelvic irradiation. Dosimetric 
correlations indicate that certain absolute dose-volume parameters 
may be useful in predicting acute toxicity with these fractionation 
schedules. 
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Purpose/Objective: Adjuvant radiotherapy after prostatectomy for 
prostate cancer has not increased enough compared to salvage 
radiotherapy in Japan. We retrospectively evaluated the outcome in 
patients receiving adjuvant radiotherapy and prognostic factors in 
Japan.  
Materials and Methods: Between 2005 and 2008, a total of 91 patients 
were referred for adjuvant radiotherapy in 23 institutions. Median 
age: 64 years (53-78 years), Median i-PSA: 11.8ng/ml (4.8-280ng/ml). 
Gleason score (GS):6 /7 /8 /9 /10 =6.6% / 37.8%/ 22.2%/ 26.7%/0%. 
Positive rates of marginal status, seminal vesicle invasion (SVI) and 
Extra-prostatic extension (EPE) were 73.3%, 28.9%, 65.6%, 
respectively. Median postoperative PSA nadir: 0.18ng/ml 
(0~2.51ng/ml). Median time from surgery to radiotherapy was 3 
months (1~12 months). A total dose of 60-65Gy was administered in 
65.6% of patients. 
Results: Median follow-up was 62 months. The 3- and 5-years bRFS 
rate for all patients were 65.6% and 56.5%, respectively. A statistically 
significant relationship existed between GS and marginal status 
(p=0.019), GS and SV (p=0.001), marginal status and EPE (p=0.017), 
type of hormonal therapy and total dose (p=0.026). The 5-year bRFS in 
patients with SV negative was 65.1% compared to 35.8% with SV 
positive (p=0.001). The 5-year bRFS in postoperative PSA nadir?0.2 
was significantly higher than postoperative PSA nadir>0.2 (68.3% vs. 
43.6%, p=0.02). The 5-year bRFS in patients who were given 
radiotherapy ?3 months from surgery tended to be more favorable 
than >3 months (p=0.069). On multivariate analysis, SV invasion and 
postoperative PSA nadir were independent prognostic factors for a 
reduced bRFS (p=0.001 and 0.018, respectively). Age, i-PSA, GS, 
marginal status, EPE, hormonal therapy and total dose were no longer 
an independent prognostic factors. 
Conclusions: The 3- and 5-years bRFS rate for all patients were 65.6% 
and 56.5%, respectively. SV invasion and postoperative PSA nadir were 
most significant prognostic factors.  
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Purpose/Objective: Cone beam CT (CBCT) images can be captured 
during delivery of VMAT rotational radiotherapy. The quality of 
simultaneous CBCT’s is affected by scatter from the megavoltage 
beam and artefact from other factors such as bowel gas. We 
developed, verified and used a novel scoring system to rate the 
quality and clinical usefulness of simultaneous CBCT’s captured during 
prostate radiotherapy. 
Materials and Methods: A novel three point scoring system was 
developed to score the quality of CBCT scans; this reflected whether 
CBCT’s were of sufficient quality to be used in clinical practice to 
verify the position of the prostate. Two oncologists and three 
radiographers each scored 25 CBCT’s in order to validate the scoring 
system. To assess intra-observer variability, each observer re-scored 5 
of the previously assessed CBCT’s. Fifteen patients with localised 
prostate cancer were treated with radical VMAT radiotherapy. 
Treatment was delivered using a single 8 MV arc on an Elekta linear 
accelerator fitted with a Synergy CBCT system. Standard and 
simultaneous CBCT’s were captured on fractions 1, 6, 11 and 16. The 
simultaneous CBCT data was reconstructed and image quality was 
improved using in-house software. Using the validated scoring system, 
2 observers scored 120 CBCT’s collected during treatment of the 15 
patients; 60 scans were standard CBCT’s and 60 were corrected 
simultaneous CBCT’s (csCBCT). 
Results: During the validation exercise, inter-observer variability was 
low; Fleiss’ kappa statistic 0.796. There was greatest agreement 
regarding the best quality scans; kappa statistic 0.910. Intra-observer 
variability was also low; mean kappa statistic 0.82 (range 0.67-1.00).  
During the second scoring exercise, observer 1 rated 60 (100%) 
standard CBCT’s and 40 (67%) csCBCT’s to be clinically useful. 
Observer 2 rated 58 (97%) standard CBCT’s and 49 (82%) csCBCT’s to 
be clinically useful. The two observers agreed that 36 (60%) csCBCT’s 
were of sufficient quality to be useful for clinical decision making. 
Further results of how each observer rated the quality of the CBCT’s 
are given in table 1. 
 







(Not clinically useful) 
0 20 
(33%) 





25 (42%) 37 
(62%) 




35 (58%) 3 (5%) 44 (73%) 4 (7%) 
 
Table 1. Results of scoring exercise for 60 standard CBCT's and 60 
corrected simultaneous CBCT's (csCBCT) 
Conclusions: Simultaneous CBCT identifies the position of the 
prostate during treatment delivery and removes the uncertainty of 
prostate motion in the interval between standard CBCT and 
treatment. This provides a more accurate assessment of target 
coverage during treatment. Simultaneous scanning also reduces the 
time the patient is on the treatment couch. The quality of 
simultaneous CBCT’s is degraded by megavoltage scatter and artefact. 
Despite this, simultaneous CBCT scanning can produce images which 
are of sufficient quality to be used for clinical decision making. 
Further development and refinement of this technique is warranted. 
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Purpose/Objective: Some patients with localised prostate cancer 
treated with SBRT have been noted to experience short-lived but 
troublesome genitourinary symptoms consisting of frequency and 
dysuria associated with a marked rise in the International Prostate 
Symptom Score (IPSS). Gastrointestinal symptoms have not been 
frequent. We investigated potential patient specific and dosimetric 
parameters that may predict for this syndrome and to suggest 
selection criteria that may reduce the incidence.  
Materials and Methods: Eighteen consecutive patients undergoing 
prostate SBRT at our institution for organ-confined prostate cancer 
had IPSS toxicity recorded at baseline and then every 2 weeks for 12 
weeks after the commencement of SBRT. The maximal recorded IPSS 
was tested against various patient parameters (prostate volume, 
bladder volume and separation at the level of the prostate) and 
features of the radiotherapy plan including bladder and urethral DVH 
parameters used in clinical practice. Patients were not catheterised 
